In a new guideline, the Canadian Task Force on Preventive Health Care (CTFPHC) “strongly” recommended against screening all adults with a standardized tool for depression, stating instead that clinicians should ask patients about their well-being and be vigilant for symptoms.

The latest guideline, published online on October 20 in CMAJ, is based on evidence suggesting that routine depression screening using a tool such as a questionnaire has “little to no effect on health.”

The update to the 2013 adult depression guideline was prompted by a confluence of factors, including the increasing prevalence of depression in Canada, the availability of new research, and awareness of the US Preventive Services Task Force (USPSTF) recommendation in favor of screening, author Eddy Lang, MD, chair of the Guideline Working Group and emergency physician at the University of Calgary, Calgary, told Medscape Medical News.

“We wanted to ensure that we did not need to change our recommendation,” he said. The recommendation remained unchanged because a systematic review of the evidence supported clinical vigilance and discussions about mental health between patients and their providers.

‘Good Clinical Care’

The working group included three external clinical and content experts; a researcher with expertise in mental health and depression screening; a physician-scientist with expertise in psychiatry, including depression management in primary care; and a psychiatrist with expertise in the prevalence of mental health disorders and risk factors.

The group commissioned a systematic review of the benefits and harms of instrument-based screening for depression among adults. The review included relevant literature from October 2018 to May 2020, updated to January 2025 for trials and to March 2025 for trial registries.

The working group also examined patient values and preferences through patient engagement surveys and focus groups at various points throughout the project. It concluded, “We recommend against screening all adults aged 18 years and older for depression using questionnaires (strong recommendation, very low-certainty evidence), based on evidence suggesting that depression screening using a screening tool has little to no effect on health.”

In contrast, the group emphasized the importance of “good clinical care,” where clinicians ask about their patients’ well-being and remain vigilant for symptoms and signs of depression.

The recommendation does not apply to adults with a personal history, current diagnosis, or clinical suspicion of a diagnosis of depression or another mental health disorder, the authors noted. It does, however, apply to those who are at a normal or higher risk for depression.

In making the recommendation, the working group considered the challenges facing Canada’s primary healthcare system and the burden of engaging in activities that consume scarce resources or that might limit access to primary care providers, especially given the lack of evidence of effectiveness above usual care.

When resources are constrained and access to primary care and specialized mental health services is limited, “patients may be using other means for diagnosis, such as online tools and questionnaires or apps,” Lang noted. “Clinicians should be wary of these [means]. If, however, patients are experiencing distress or possible symptoms of depression, they should seek help, and all patient encounters should include a mental health check when warranted.”

“Patients should always feel comfortable to discuss mental health issues and should never be dismissed,” he added. “Sometimes a transient period of sadness may not be a true depression and applying the label may do more harm than good.”

Importantly, he emphasized, “We remain in disagreement with the USPSTF because it based its recommendations on trials that coupled depression screening with treatment. The trials looking at the screening interventions alone were convincingly negative: that is, no benefit to screening, and the false-positive rate is in excess of 10%.”

Not ‘Doing Less’

“Moving to a strong recommendation against routine, instrument-based screening of all adults makes sense, given the evidence,” said Peter Bieling, PhD, professor of psychiatry and behavioral neurosciences at McMaster University in Hamilton, Ontario, who was not involved in development of the guideline.

“It may be one of those areas where what happens in careful studies defies what one might think when making an educated guess,” he told Medscape Medical News. “Depression is so common, and possibly hidden in plain view, that universal screening might seem like a sensible solution. But when you isolate ‘screening everyone’ from usual good care, you don’t see outcome gains, but you do create false positives and downstream workload.”

“Asking in a clinical encounter might get a better answer precisely because it’s happening in the context of an ongoing patient-provider relationship,” he added. “The way it’s asked might be more sensitive and more likely to get a meaningful answer.”

The guideline contains three key messages, according to Bieling. The first is not to conduct blanket screening, but to ask about a patient’s mood when something during the visit points in that direction. The second is to use questionnaires for assessment and monitoring. Standardized scales are useful markers when a concern has arisen but should not be used as “universal gates,” he said.

The third message is to think about capacity. “Low-value screening takes time and resources. The resources put into universal [screening tool] administration could instead be redeployed to people actively seeking help,” said Bieling.

The message of the guideline is not to do less for depression, he added. “It’s do the right things at the right time: notice, ask, assess, rule out, and follow through.” Nor is the guideline saying that structured depression scales are flawed, Bieling said.

Along with the new guideline, the CTFPHC provided relevant tools for clinicians and patients, including a public infographic, clinician infographic, podcast, and documents related to the study.

The CTFPHC is funded by the Public Health Agency of Canada. Lang and Bieling declared having no competing interests.

Marilynn Larkin, MA, is an award-winning medical writer and editor whose work has appeared in numerous publications, including Medscape Medical News and its sister publication MDedge, The Lancet (where she was a contributing editor), and Reuters Health.